Last Updated: 09/26/2026
Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 11 publications
Benralizumab for Eosinophil-Related Cutaneous Adverse Events of Anticancer Therapy: A Phase II Trial.
Journal: Clinical cancer research : an official journal of the American Association for Cancer Research
Published: August 29, 2025
Use of Dupilumab to Manage Antibody-Drug Conjugate-Induced Cutaneous Toxicities.
Journal: JAMA dermatology
Published: July 30, 2025
Oral minoxidil for late alopecia in cancer survivors.
Journal: Breast cancer research and treatment
Published: January 24, 2024
Timing of exercise therapy when initiating adjuvant chemotherapy for breast cancer: a randomized trial.
Journal: European heart journal
Published: October 31, 2022
Endocrine Therapy-Induced Alopecia in Patients With Breast Cancer.
Journal: JAMA dermatology
Published: April 12, 2018
The PARP Inhibitor Veliparib Can Be Safely Added to Bendamustine and Rituximab and Has Preliminary Evidence of Activity in B-Cell Lymphoma.
Journal: Clinical cancer research : an official journal of the American Association for Cancer Research
Published: December 07, 2016
Decreased gastrointestinal toxicity associated with a novel capecitabine schedule (7 days on and 7 days off): a systematic review.
Journal: NPJ breast cancer
Published: January 20, 2015
Phase II study of paclitaxel given once per week along with trastuzumab and pertuzumab in patients with human epidermal growth factor receptor 2-positive metastatic breast cancer.
Journal: Journal of clinical oncology : official journal of the American Society of Clinical Oncology
Published: December 31, 2014
A phase 1 study evaluating the combination of an allosteric AKT inhibitor (MK-2206) and trastuzumab in patients with HER2-positive solid tumors.
Journal: Breast cancer research : BCR
Published: May 16, 2013
Showing 1-11 of 11
Last Updated: 09/26/2026